TMCnet News

Pennystockchaser.com: www.pennnystockchaser.com: Penny Stock Chaser Alerts, December 9, 2009: AVNR, MSCC, FEIM and GENZ
[December 10, 2009]

Pennystockchaser.com: www.pennnystockchaser.com: Penny Stock Chaser Alerts, December 9, 2009: AVNR, MSCC, FEIM and GENZ


(M2 PressWIRE Via Acquire Media NewsEdge) Pennystockchaser.com Alerts include AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR); Microsemi Corporation (Nasdaq: MSCC); Frequency Electronics, Inc. (Nasdaq: FEIM) and Genzyme Corporation (NASDAQ: GENZ) -- December 9, 2009 AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) trading at $1.89 on a volume of 2.75M shares AVANIR Pharmaceuticals Presents Zenvia Phase III Results in Amyotrophic Lateral Sclerosis Patient Cohort at the International Symposium on ALS / MND ALISO VIEJO, Calif., Dec 09, 2009 -- AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced additional data from the subset of patients with amyotrophic lateral sclerosis (ALS) enrolled in the confirmatory Phase III STAR trial. This double-blind study evaluated two doses of the investigational drug Zenvia(TM) (dextromethorphan/quinidine) compared to placebo in the treatment of patients with pseudobulbar affect (PBA) secondary to ALS or multiple sclerosis (MS). In the ALS patient subset, both Zenvia 30/10 mg and Zenvia 20/10 mg met the primary efficacy endpoint by significantly reducing daily PBA episode rates compared to placebo (p<0.0001 for both treatment groups). These results were presented today during a podium presentation at the 20th International Symposium on ALS/MND in Berlin, Germany.



ABOUT AVANIR AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead product candidate, Zenvia, is being developed for the treatment of pseudobulbar affect (PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain. AVANIR sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva(R) (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.

-- December 9, 2009 Microsemi Corporation (Nasdaq:MSCC) trading at $16.47 on a volume of 255,566 shares.


Microsemi Launches Line of Linear MOSFET Power Modules Designed for High System Reliability With a Minimum of Devices IRVINE, Calif., Dec 9, 2009 -- Microsemi Corporation (Nasdaq:MSCC), a leading manufacturer of high performance analog mixed signal integrated circuits and high reliability semiconductors, has introduced a new line of linear MOSFET power modules for applications ranging from factory automation to electric vehicles and industrial power supplies.

About Microsemi Microsemi Corporation, with corporate headquarters in Irvine, California, is a leading designer, manufacturer and marketer of high performance analog and mixed-signal integrated circuits and high reliability semiconductors. The company's semiconductors manage and control or regulate power, protect against transient voltage spikes and transmit, receive and amplify signals.

-- December 9, 2009 Frequency Electronics, Inc. (Nasdaq:FEIM) trading at $4.53 on a volume of 1,013 shares Frequency Electronics, Inc. Announces Second Quarter Fiscal Year 2010 Results MITCHEL FIELD, N.Y., Dec 9, 2009 -- Frequency Electronics, Inc. (Nasdaq:FEIM) reported revenues of $11.4 million for the second quarter of fiscal year 2010, which ended October 31, 2009, compared to $12.4 million for the preceding quarter and $14.0 million for the same period of fiscal 2009. Revenues for the first six months of fiscal 2010 were $23.8 million compared to $27.1 million for the same period of fiscal 2009.

About Frequency Electronics Frequency Electronics, Inc. is a world leader in the design, development and manufacture of high precision timing, frequency control and synchronization products for space and terrestrial applications. Frequency's products are used in commercial, government and military systems, including satellite payloads, missiles, UAVs, aircraft, GPS, secure radios, SCADA, energy exploration and wireline and wireless communication networks. Frequency has received over 60 awards of excellence for achievements in providing high performance electronic assemblies for over 120 space programs. The Company invests significant resources in research and development and strategic acquisitions world-wide to expand its capabilities and markets. Subsidiaries and Affiliates: Gillam-FEI provides expertise in wireline network synchronization and SCADA; FEI-Zyfer provides GPS and secure timing ("SAASM") capabilities for critical military and commercial applications; FEI-Asia provides cost effective manufacturing and distribution capabilities in a high growth market. Frequency's Morion affiliate supplies high-quality, cost effective quartz oscillators and components. Elcom Technologies provides added resources for state-of-the-art RF microwave products. Additional information is available on the Company's website: www.frequencyelectronics.com.

-- December 9, 2009 Genzyme Corporation (NASDAQ: GENZ) closed at $49.00 on a volume of 1.25M shares.

Genzyme Laboratory Recognized for Quality First Commercial Genetic Testing Facility to Achieve Accreditation From College of American Pathologists CAMBRIDGE, Mass., Dec 09, 2009 -- Genzyme Corporation (NASDAQ: GENZ) announced today that its genetic testing laboratory located in Phoenix, Arizona, has obtained the CAP 15189SM Accreditation to the International Standards Organization 15189:2007 Standard for laboratories from the College of American Pathologists. This accreditation recognizes the laboratory's technical competence and continual quality management and underscores Genzyme's commitment to improved patient outcomes by providing reliable test results.

About Genzyme One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

About PennyStockChaser.com PennyStockChaser.com's alerts are daily e-mail on stocks that are hot in the market. These include stocks with huge volume, penny stocks, new 52 weeks high or lows, stocks with technical indicators and much more. Our stock alerts have done very well in the last couple of weeks.

PennyStockChaser.com is a leading stock website that provides free daily alerts on stocks that are moving up. PennyStockChaser.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at [email protected] PennyStockChaser.com is an independent electronic publication that provides information on selected publicly traded companies. PennyStockChaser.com is not a registered investment advisor or broker-dealer. PennyStockChaser.com's affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS

[ Back To TMCnet.com's Homepage ]